Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:MIRM NYSE:RDY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$194.82-2.3%$187.25$118.03▼$208.16$11.92B0.39479,620 shs143,741 shsMIRMMirum Pharmaceuticals$73.33-2.6%$63.98$36.88▼$78.10$3.67B0.92524,000 shs267,167 shsRDYDr. Reddy's Laboratories$14.95+0.8%$14.33$12.26▼$16.19$12.48B0.321.72 million shs329,748 shsSMMTSummit Therapeutics$19.50+1.4%$25.01$15.55▼$36.91$14.51B-1.023.80 million shs1.96 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.11%+0.86%+2.44%+12.70%+33.91%MIRMMirum Pharmaceuticals+2.98%-0.88%+15.59%+49.62%+98.73%RDYDr. Reddy's Laboratories-0.34%+0.65%+4.51%-2.67%-5.98%SMMTSummit Therapeutics+6.30%+3.39%-24.14%-6.47%-21.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$194.82-2.3%$187.25$118.03▼$208.16$11.92B0.39479,620 shs143,741 shsMIRMMirum Pharmaceuticals$73.33-2.6%$63.98$36.88▼$78.10$3.67B0.92524,000 shs267,167 shsRDYDr. Reddy's Laboratories$14.95+0.8%$14.33$12.26▼$16.19$12.48B0.321.72 million shs329,748 shsSMMTSummit Therapeutics$19.50+1.4%$25.01$15.55▼$36.91$14.51B-1.023.80 million shs1.96 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.11%+0.86%+2.44%+12.70%+33.91%MIRMMirum Pharmaceuticals+2.98%-0.88%+15.59%+49.62%+98.73%RDYDr. Reddy's Laboratories-0.34%+0.65%+4.51%-2.67%-5.98%SMMTSummit Therapeutics+6.30%+3.39%-24.14%-6.47%-21.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$244.3625.43% UpsideMIRMMirum Pharmaceuticals 3.11Buy$74.441.52% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9513.42% UpsideSMMTSummit Therapeutics 2.56Moderate Buy$31.8763.39% UpsideCurrent Analyst Ratings BreakdownLatest MIRM, SMMT, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/16/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.009/16/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/16/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M30.30N/AN/A($1.88) per share-103.63MIRMMirum Pharmaceuticals$429.16M8.58N/AN/A$4.70 per share15.60RDYDr. Reddy's Laboratories$3.81B3.27$1.04 per share14.39$4.73 per share3.16SMMTSummit Therapeutics$700K20,696.86N/AN/A$0.53 per share36.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A811.73N/A-54.94%N/A-24.31%11/13/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.6418.236.0016.99%17.25%11.63%11/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest MIRM, SMMT, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.47%N/A10.61%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest MIRM, SMMT, RDY, and ASND DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69MIRMMirum Pharmaceuticals1.213.132.97RDYDr. Reddy's Laboratories0.011.891.36SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AMIRMMirum PharmaceuticalsN/ARDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%MIRMMirum Pharmaceuticals14.36%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableRDYDr. Reddy's Laboratories27,811834.92 million818.23 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableMIRM, SMMT, RDY, and ASND HeadlinesRecent News About These CompaniesJim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”September 19 at 8:45 AM | msn.comBarclays Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Strong Sell"September 19 at 6:47 AM | marketbeat.comRockland Trust Co. Buys Shares of 400,000 Summit Therapeutics PLC $SMMTSeptember 19 at 5:32 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 18 at 10:00 AM | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at BarclaysSeptember 18 at 8:14 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at BarclaysSeptember 18 at 3:11 AM | americanbankingnews.comSummit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough PotentialSeptember 17 at 10:54 PM | fxempire.comFSummit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC WainwrightSeptember 17 at 8:11 AM | marketbeat.comFocus Partners Wealth Boosts Stake in Summit Therapeutics PLC $SMMTSeptember 17 at 3:07 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)September 17 at 2:20 AM | americanbankingnews.comSummit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 16 at 4:31 PM | globenewswire.comInsiders Are Aggressively Buying These 5 StocksSeptember 16 at 1:51 PM | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying ActivitySeptember 14, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 SharesSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 SharesSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 13, 2025 | prnewswire.comSiren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMTSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up After Insider Buying ActivitySeptember 13, 2025 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?September 12, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRM, SMMT, RDY, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$194.82 -4.56 (-2.28%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Mirum Pharmaceuticals NASDAQ:MIRM$73.33 -1.99 (-2.64%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Dr. Reddy's Laboratories NYSE:RDY$14.94 +0.12 (+0.78%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$19.50 +0.27 (+1.42%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
